Resistance Shapes New Therapeutic Options in ER-Positive Breast Cancer

Jane De Lartigue, PhD
Published: Monday, Aug 19, 2019
Although hormonal manipulation was an established part of breast cancer treatment long before the underlying biology of the disease was characterized,1 advancements in the understanding of estrogen receptor (ER) signaling are rapidly changing the therapeutic landscape. In the past 4 years,2-4 CDK4/6 inhibitors have emerged as a new class of therapy for patients with hormone receptor–positive, HER2-negative disease, yielding impressive survival gains when added to endocrine therapy in the frontline setting and after progression.5

Table. Select Clinical Trials of Novel Agents Aimed at Endocrine Therapy Resistance

Table. Select Clinical Trials of Novel Agents Aimed at Endocrine Therapy Resistance

Figure. Endocrine Therapy in Action19

Figure. Endocrine Therapy in Action19
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x